Oxford Lane Capital Corp (OXLC) Stock Price Today
Aura AI Summary
Key Stats
- $824.65MMarket Cap
- -Volume
- FinancialsSector
- $18.7552W High
- $8.1552W Low
- -Typical Hold Time
- -Enterprise Value
- 28.42%Div Yield
- -Trading Activity
Track Oxford Lane Capital Corp (OXLC) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Oxford Lane Capital Corp has traded between a low of $8.15 and a high of $18.75, highlighting its annual price range. Buy and sell Oxford Lane Capital Corp shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Most Recent News
Global AI in Medical Coding market to reach $10.6B by 2035 with 13.5% CAGR, driven by healthcare digital transformation.
The global AI in Medical Coding market, valued at $3 billion in 2025, is projected to grow to $10.6 billion by 2035 at a 13.5% CAGR. Growth is fueled by increasing adoption of AI technologies in healthcare for automated coding, fraud detection, and r...

OMODA 4 debuts in Southeast Asia with AI cockpit tech, targeting young users and smart mobility growth.
OMODA & JAECOO launched the OMODA 4 SUV in Southeast Asia at the OMODA SUPER AI NIGHT event in Jakarta, showcasing its AI-powered cockpit technology integrated with ByteDance Seed large language model. The event highlighted the brand's strategy to ex...

AnaptysBio shifts to royalty management, focusing on growing Jemperli royalties from GSK.
AnaptysBio has transformed into a royalty management company centered on Jemperli, an oncology drug commercialized by GSK. The company now operates with minimal costs, targeting a 95% EBIT margin and holding over $140 million in net cash, eliminating...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.